Anti-Angiopoietin 2/ANGPT2 Antibody (FITC Conjugate)

ANGPT2, also known as ANG2 or Angiopoietin 2, is a protein that in humans is encoded by the ANGPT2 gene. It is mapped to 8p23.1. ANGPT2 is a naturally occurring antagonist of ANG1 that competes for binding to the TIE2 receptor and blocks ANGPT1-induced TIE2 autophosphorylation during vasculogenesis. The encoded protein disrupts the vascular remodeling ability of ANGPT1 and may induce endothelial cell apoptosis. ANGPT2 was significantly increased in plasma and alveolar edema fluid in adults with acute lung injury compared to controls or patients with hydrostatic pulmonary edema, tracheal. ANGPT2 was also significantly increased in neonates with respiratory distress syndrome who developed bronchopulmonary edema. It is also a mediator of epithelial necrosis with an important role in hyperoxic acute lung injury and pulmonary edema.

E.coli-derived human Angiopoietin 2 recombinant protein (Position: Y19-N348). Human Angiopoietin 2 shares 84% and 85% amino acid (aa) sequences identity with mouse and rat Angiopoietin 2, respectively.

Binds to TEK/TIE2, competing for the ANGPT1 binding site, and modulating ANGPT1 signaling. Can induce tyrosine phosphorylation of TEK/TIE2 in the absence of ANGPT1. In the absence of angiogenic inducers, such as VEGF, ANGPT2-mediated loosening of cell-matrix contacts may induce endothelial cell apoptosis with consequent vascular regression. In concert with VEGF, it may facilitate endothelial cell migration and proliferation, thus serving as a permissive angiogenic signal. .

Store at -20℃ for one year from date of receipt. After reconstitution, at 4℃ for one month. It can also be aliquotted and stored frozen at -20℃ for six months. Avoid repeated freeze-thaw cycles.